ERBB2 and cancer: Given the relative high inhibitory potency of MdOS against HER-2, EGFR and VEGFR2, together with the fact that HER-2, EGFR and VEGFR2 are the most verified targets in cancer therapy, we took these three kinases as representatives to probe MdOS -driven PTKs-associated events.